Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 11, Issue 11, Pages 1563-1573Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.11.11.1563
Keywords
erectile dysfunction; nitric oxide; phosphodiesterase type 5; Rho-kinase; sildenafil; soluble guanylate cyclase
Categories
Ask authors/readers for more resources
Approximately 50% of men aged over 40 suffer from male erectile dysfunction. Treatment options have widened since the launch of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil citrate (Viagra(TM)). However, a certain portion of the patient population, such as diabetics, do not gain significant benefit from PDE5 inhibitors, possibly due to a lack of endogenous nitric oxide. Therefore, new treatment modalities based on the absence of endogenous nitric oxide have been developed. Among them are Rho-kinase inhibitors, soluble guanylate cyclase activators and nitric oxide-releasing PDE5 inhibitors. The available data concerning these compounds will be summarised and their therapeutic potential for male erectile dysfunction will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available